Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by January 16, 2026 [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Skye to discuss their legal options, particularly those who purchased securities between November 4, 2024, and October 3, 2025 [1][3]. - The firm has filed a federal securities class action against Skye, with a deadline for investors to seek lead plaintiff status by January 16, 2026 [3][7]. - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about the effectiveness of nimacimab and overstating its clinical and commercial prospects [5][6]. Group 2: Stock Performance and Impact - Following the announcement of disappointing clinical trial results for nimacimab on October 6, 2025, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 per share [6]. - The press release indicated that the primary endpoint of weight loss was not achieved in the clinical trial, and drug exposure was lower than expected, suggesting a need for higher dosing [6]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm encourages anyone with information regarding Skye's conduct, including whistleblowers and former employees, to contact them for further investigation [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026 [1]. Group 1: Class Action Details - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that Skye's management made materially false and misleading statements regarding the effectiveness and prospects of its product, nimacimab, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements recovered for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026 [1]. Group 1: Class Action Details - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by January 16, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its performance in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical and commercial prospects [5]. - The claims suggest that when the true information became public, investors suffered damages due to the misleading statements made by the defendants [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025, inclusive [1]. - Investors who purchased Skye securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab [4]. - Specifically, it is claimed that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for lead plaintiff applications in a securities class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [3][5]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at Rosen Law Firm have received recognition from Lawdragon and Super Lawyers, emphasizing the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [3]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Skye Bioscience made materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab [4]. - Specifically, it is claimed that nimacimab was less effective than represented, and its clinical and commercial prospects were overstated [4]. - The lawsuit asserts that these misleading statements resulted in investor damages when the true information became public [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Skye's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding the efficacy of its product, nimacimab [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff appointments set for January 16, 2026 [2]. - The complaint alleges that Skye's public statements were materially misleading, as the company failed to demonstrate the efficacy of nimacimab as previously claimed [2]. Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group to participate in the lawsuit [3]. - There is no cost or obligation for shareholders to enroll in the case, and they will receive updates through a portfolio monitoring software [3]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 4, 2024, and October 3, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was allegedly less effective than represented [2] - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3] Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Points - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules targeting G protein-coupled receptors to treat obesity and metabolic diseases, with nimacimab as its lead product candidate [1] - A class action lawsuit has been filed on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025, alleging that the company misled investors about the viability of nimacimab [1][2] - The lawsuit claims that during the class period, Skye failed to disclose that nimacimab was less effective than represented, leading to overstated clinical and commercial prospects [2] Company Developments - On October 6, 2025, Skye released topline data from its 26-week Phase 2a CBeyond™ study of nimacimab, revealing that the drug did not achieve the primary endpoint of weight loss compared to placebo, and indicated lower than expected drug exposure [3] - Following the announcement, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share on the same day [3] Legal Actions - Shareholders interested in participating in the class action must submit their papers by January 16, 2026, to serve as lead plaintiff, representing other class members in the litigation [4] - Shareholders are not required to participate in the case to be eligible for recovery, and can choose to remain absent class members [4]